| HSIC |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.27 vs. cons $1.2426 |
MEDIUM |
| HSIC |
Report |
Revenue |
IN-LINE |
pred ~$3.40B vs. cons $3.3718B |
MEDIUM |
| HSIC |
Report |
Dental revenue |
IN-LINE |
pred ~$1.80B vs. cons $1.7858B |
MEDIUM |
| HSIC |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide $5.23-$5.37 vs. cons $5.3509 |
MEDIUM |
| HSIC |
Guide |
FY2026 revenue growth |
UNCHANGED |
guide 3%-5% vs. cons $13.7472B |
MEDIUM |
| HSIC |
Guide |
H2 value-creation cadence |
UNCHANGED |
reaffirm Q3/Q4 savings acceleration vs. Q3 EPS cons $1.3654 |
MEDIUM |
| HSIC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
LOW |
| HSIC |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE — beat/maintain does not drive FY revisions |
LOW |